SpeeDx has received the CE-IVD mark for its PlexPCR VHS multiplex quantitative polymerase chain reaction (qPCR) test. The test offers a single-well solution to cover the detection and differentiation of the main causes of genital and oral lesions: herpes simplex virus types 1 and 2 (HSV-1, HSV-2), Treponema pallidum (syphilis) and varicella zoster virus (VZV).
Validated for use on multiple lesion specimen types, the test is designed to streamline workflows and support rapid, appropriate clinical management of infections with similar symptoms.The SpeeDx portfolio is based on advanced multiplex technology, and the PlexPCR VHS test is the latest to gain the CE-IVD mark, supplementing the company’s range of infectious disease and antibiotic resistance detection tests.
There are diagnostic challenges in treating herpes simplex virus types 1 and 2 (HSV-1/2), T. pallidum (syphilis) and varicella zoster virus (VZV), All four infections present with clinically similar symptoms – appearing as lesions or ulcers on the skin, mouth or
genital area. Due to the similarities in clinical presentation, molecular-based tests are recommended to detect and differentiate the cause of infection. Treatments for HSV-1/2 and VZV include acyclovir, famciclovir and valacyclovir; however, appropriate dosage requires correct identification of the causative virus, whereas T. pallidum infection can be treated with penicillin-based antibiotics.